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A Meta-Analysis of Remote
Monitoring of Heart Failure Patients
Catherine Klersy, MD, MSC,* Annalisa De Silvestri, MSC,* Gabriella Gabutti, MA,†
François Regoli, MD,*‡ Angelo Auricchio, MD‡
Pavia, Italy; and Lugano, Switzerland
Objectives The purpose of this study was to assess the effect of remote patient monitoring (RPM) on the outcome of
chronic heart failure (HF) patients.
Background RPM via regularly scheduled structured telephone contact between patients and health care providers or elec-
tronic transfer of physiological data using remote access technology via remote external, wearable, or implant-
able electronic devices is a growing modality to manage patients with chronic HF.
Methods After a review of the literature published between January 2000 and October 2008 on a multidisciplinary heart
failure approach by either usual care (in-person visit) or RPM, 96 full-text articles were retrieved: 20 articles re-
porting randomized controlled trials (RCTs) and 12 reporting cohort studies qualified for a meta-analysis.
Results Respectively, 6,258 patients and 2,354 patients were included in RCTs and cohort studies. Median follow-up
duration was 6 months for RCTs and 12 months for cohort studies. Both RCTs and cohort studies showed that
RPM was associated with a significantly lower number of deaths (RCTs: relative risk [RR]: 0.83, 95% confidence
interval [CI]: 0.73 to 0.95, p  0.006; cohort studies: RR: 0.53, 95% CI: 0.29 to 0.96, p  0.001) and hospital-
izations (RCTs: RR: 0.93, 95% CI: 0.87 to 0.99, p  0.030; cohort studies: RR: 0.52, 95% CI: 0.28 to 0.96, p 
0.001). The decrease in events was greater in cohort studies than in RCTs.
Conclusions RPM confers a significant protective clinical effect in patients with chronic HF compared with usual care. (J Am
Coll Cardiol 2009;54:1683–94) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.017b
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tatients with chronic heart failure (HF) frequently experi-
nce repeated hospitalizations that are not only a result of
rogression of underlying disease but more often due to
oor adherence to drug therapy, inadequate drug therapy,
hanges in diet, poor self-care, and inadequate patient
upport. Approximately 70% of all direct and indirect costs
enerated by HF patients are due to hospitalization (1).
ecent guidelines of both European and American scientific
ocieties recommended a multidisciplinary care approach
hat coordinates care along the continuum of HF and
hroughout the chain of care delivery by various services
ithin the health care systems (1,2)
rom the *Service of Biometry and Clinical Epidemiology and †Scientific Documen-
ation Center, Scientific Direction Fondazione IRCCS Policlinico San Matteo, Pavia,
taly; and the ‡Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano,
witzerland. Dr. Klersy is a consultant to Boston Scientific and Medtronic. Dr. De
ilvestri is a consultant to Boston Scientific. Dr. Gabutti is a consultant to Boston
cientific. Dr. Auricchio is a consultant to Philips, Medtronic, Biotronik GmbH, and
orin and has received speaker fees from GE Healthcare, Philips, Medtronic,
iotronik GmbH, and Sorin.n
Manuscript received May 25, 2009; revised manuscript received August 31, 2009,
ccepted August 31, 2009.The multidisciplinary HF care approach is implemented
y in-person follow-up visits and is regarded as usual care of
F patients. More recently, alternative approaches have
een proposed including regularly scheduled structured
elephone contact between patients and health care provid-
rs and electronic transfer of physiological data using remote
ccess technology via external, wearable, or implantable
lectronic devices. This latter approach allows frequent or
ontinuous assessment of some physiological parameters
elated to HF exacerbation, and such technology-based
onitoring is the base for early detection of HF worsening,
hus permitting remote disease management (1).
Results of some randomized controlled trials (RCTs)
3–22) and several observational studies (23–34) support the
ypothesis that the multidisciplinary care approach or the
anagement strategy of structured communication with the
ealth care provider may reduce both the incidence of
ospitalizations and death and eventually related costs with
espect to more traditional follow-up of patients with
hronic HF. Moreover, recent systematic reviews and meta-
nalyses provided further evidence in favor of implementa-
ion of telemonitoring in chronic HF patients (35–38). Of
ote, guidelines recommend remote monitoring of symp-
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Remote Patient Monitoring in Heart Failure October 27, 2009:1683–94toms (including drug adverse ef-
fects) and signs of HF (Class I
recommendation, Level of Evi-
dence: C) (1). Since the last re-
view by Clark et al. (35), which
exclusively included RCTs and
all published articles until mid-
2006, several observational stud-
ies and RCTs have become avail-
able (6,9,10,21).
To update earlier systematic
eviews, we conducted a literature search including both
CTs and observational studies and performed a meta-
nalysis of the use of telemonitoring in chronic HF and its
elated outcomes compared with usual care of HF patients.
ethods
ibliographic search. The National Guideline Clearing-
ouse, PubMed, EMBASE, Cinhail, and the Cochrane Li-
rary databases were searched throughout October 2008 using
he following search criteria: 1) full-text articles in peer-
eviewed journals published between January 2000 and Octo-
er 2008 in which at least 2 treatment arms were evaluated
thus uncontrolled studies were excluded); 2) RCTs or obser-
ibliographic Search StrategyTable 1 Bibliographic Search Strategy
Database Access Date
National Guideline
Clearinghouse
July 2, 2008 Heart failure remote monitori
October 23, 2008 Heart failure remote monitori
PubMed July 4, 2008 (“Heart Failure”[Mesh] AND “T
“remote patient monitoring
Limits:
Published from January 1,
English, French, German, It
October 23, 2008 [(“Heart Failure”[Mesh] AND “
“remote patient monitoring
2008/07/03:2008/10/23
Limits:
Published from January 1,
English, French, German, It
EMBASE July 4th, 2008 [(“heart failure”/exp AND “tel
[french]/lim OR [german]/l
py)] OR [“heart failure”/exp
[french]/lim OR [german]/l
AND [2000-2008]/py)]
October 23, 2008 [(“heart failure”/exp AND “tel
[french]/lim OR [german]/l
[“heart failure”/exp AND “re
[french]/lim OR [german]/l
AND [2008]/py)]
Cinhail July 4, 2008 Heart failure AND (telemedici
Limits:
Published from January 20
Language: English, French,
October 23, 2008 Heart failure AND (telemedici
Limits:
Published from July 2000 t
English, French, German, It
Cochrane Library July 4, 2008 (heart failure):ti, from 2000 t
October 23, 2008 (heart failure):ti, in 2008 in C
Abbreviations
and Acronyms
CI  confidence interval
HF  heart failure
RCT  randomized
controlled trial
RPM  remote patient
monitoring
RR  relative riskNumber of new reviews from July 4 to October 23, 2008.ational cohort (C) studies; and 3) language of publica-
ion could be English, Spanish, German, French, or Italian
Table 1). A total of 253 abstracts were retrieved; however,
6 studies were excluded because they were simultaneously
resent in more than 1 database; thus, 197 abstracts were
nally collected and reviewed.
ata extraction. For each article, we collected the following
nformation: type of study (multicenter or single center), total
umber of patients included in the trial, number of arms/
eriods, mean duration of follow-up, age, sex, New York Heart
ssociation functional class, and left ventricular ejection frac-
ion of included patients and for each arm, person-years of
ollow-up, and the modality of care. Three different approaches
f care were identified: 1) a usual care approach, which referred
o in-person visits at the doctor’s office, at a multidisciplinary
utpatient clinic, or at emergency department without addi-
ional phone calls to and from the patient; 2) a telephone
onitoring approach including regularly scheduled structured
elephone contact between patients and health care providers
with or without home visits) and reporting of symptoms
nd/or physiological data; and 3) a technology-assisted moni-
oring approach relying on information communication tech-
ology, with transfer of physiological data collected via remote
at the patient’s home) external monitors or via cardiovascular
earch Strategy No. of Articles Found
13
0
dicine”[Mesh]) OR (“heart failure” AND
to July 4, 2008
panish
99
edicine”[Mesh]) OR (“heart failure” AND
(2008/07/03:2008/10/23[mhda] OR
to July 4, 2008
panish
7
ine”/exp AND [embase]/lim AND ([english]/lim OR
[italian]/lim OR [spanish]/lim) AND [2000-2008]/
remote patient monitoring” AND ([english]/lim OR
[italian]/lim OR [spanish]/lim) AND [embase]/lim
75
ine”/exp AND [embase]/lim AND ([english]/lim OR
[italian]/lim OR [spanish]/lim) AND [2008]/py)] OR
patient monitoring” AND ([english]/lim OR
[italian]/lim OR [spanish]/lim) AND [embase]/lim
11
remote patient monitoring)
uly 2008
n, Italian, Spanish
38
remote patient monitoring)
ber 2008
panish
0
in Cochrane Reviews 10
e Reviews 0*S
ng
ng
eleme
”)
2000,
alian, S
Telem
”)] AND
[edat])
2000,
alian, S
emedic
im OR
AND “
im OR
emedic
im OR
mote
im OR
ne OR
00 to J
Germa
ne OR
o Octo
alian, S
o 2008
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October 27, 2009:1683–94 Remote Patient Monitoring in Heart Failuremplantable electronic devices. Finally, the latter 2 approaches
ere collectively considered and identified as remote patient
onitoring (RPM).
For each of these approaches, great attention was paid to
etrieval of information about clinical and cardiovascular
arameters monitored such as symptoms, body weight,
lood pressure, electrocardiogram, heart rate, arrhythmias,
hock device, heart rate variability, activity log, oxygen
aturation, and right ventricular pressures.
The following outcomes were considered: death from
ny cause, first hospitalization for any cause and first
ospitalization for HF, and a combined end point of first
ospitalization or death from any cause. Only a few
rticles reported the cause-specific mortality, and, thus,
his was not included.
Two authors (C.K. and A.D.S.) reviewed all abstracts
nd selected articles to ensure that they met the inclusion
riteria. Each of them separately extracted the informa-
ion from the articles, and whenever a discrepancy was
oted, it was reconciled by consensus. The quality of the
tudy was rated based on adherence to the CONSORT
nd STROBE statements and graded on a 0 to 10 visual
nalog scale.
eta-analysis. The primary end point of the study was the
omparison of the cumulative incidence of events (number
f patients with events/total number of patients per arm)
etween the usual care approach and RPM strategies
Data base research
197 abstract evaluated
64 full-text selected
133 abstract eliminated (not pertinent)
63 full-text retrieved
1 full-text unretrievable
64 papers excluded *
•Duplicated publications n=6
•Review/meta-analysis n=22
•Not pertinent n=21
•Insufficient info n=11
•Study protocol n=3
•Lack of usual care arm=1
20 RCT
Figure 1 Study Flow Chart Displaying Study Disposition
RCT  randomized controlled trial.telephone and technology-assisted monitoring approaches) tor each of the outcomes considered (death from any cause,
rst hospitalization for any cause, and hospitalization for
F), as well as for the combined outcome of first hospital-
zation or death from any cause. Death and hospitalization
rom any cause were assessed separately for RCTs and
ohort (between) studies, whereas hospitalization for HF
ould be assessed for RCTs only. A secondary analysis of
he primary end point comparing incidence rates of events
number of events/total person time per arm) gave similar
esults (data not shown).
To assess the stability of our conclusions, we performed a
eries of sensitivity analyses: 1) comparison of the cumula-
ive incidence of events with the usual care approach with
hat of the telephone monitoring and the technology-
ssisted monitoring approach; 2) comparison of the cumu-
ative incidence of events with the usual care approach with
hat of the RPM approach, according to duration of
ollow-up (6 and 6 months) and study quality (8 and
8 on a visual analog scale).
The relative risk (RR) and 95% confidence interval (CI)
or each outcome in each study were calculated. Study RRs
ere then pooled according to the Mantel-Haenszel fixed-
ffects method. To better account for differences among
tudies, we also fitted DerSimonian and Laird random-
ffects models. Statistical heterogeneity was evaluated by the
ochran Q test and measured by the I2 statistic. When the
2 statistic was20%, we considered the random-effects RR
+ 33  full-text retrieved
from bibliography
96 full-text
apers included
12 cohort studies
6 within arms6 between arms32 po be preferable. The presence of severe publication and
o
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Remote Patient Monitoring in Heart Failure October 27, 2009:1683–94ther biases, for each outcome, was excluded by funnel plots
Online Appendix).
Stata version 10.1 (Stata Corp., College Station, Texas)
as used for computation.
esults
dentification of articles. Sixty-three full-text articles were
etrieved from 197 abstracts; an additional 33 full-text
tudy Design and Population: SummaryTable 2 Study Design and Population: Summary
Characteristic
RCT
(n  20)
Cohort Study
(n  20)
Year of publication
2001 3 0
2002 4 0
2003 2 1
2004 2 2
2005 3 4
2006 2 2
2007 0 2
2008 4 1
Multicenter study, n (%) 9 (45) 2 (17)
Parallel group design, n (%) 20 (100) 6 (50)
No. of patients
Total 6,258 2,354
Median over study 182 123
25th to 75th percentiles 100–382 73–354
Range 34–1,518 24–502
Sex distribution,* n (%)
Male 3,995 (64) 1,163 (60)
Female 2,263 (36) 765 (40)
Study mean age distribution, yrs
Median over study 70 66
25th to 75th percentiles 63–72 60–74
Range 54–78 59–81
Left ventricular ejection fraction, %†
Median over study 35 40
25th to 75th percentiles 25–38 35–44
Range 22–43 35–44
NYHA functional class III to IV,‡ n (%) 3,306 (54) 480 (83)
Study mean follow-up duration, months
Median over study 6 12
25th to 75th percentiles 4–12 8–12
Range 2–18 2–17
Study mean follow-up duration (months),
categorized, n (%)
0–3 5 (25) 1 (8)
3–6 6 (30) 1 (8)
6–12 7 (35) 9 (75)
12–18 2 (10) 1 (8)
Study quality rating, n (%)
8 10 (50) 10 (83)
8 10 (50) 2 (17)
In one observational study, sex distribution was not provided; thus, the sum of the number of male
nd female subjects enrolled is less than the total number of subjects. †Left ventricular ejection
raction available in 9 RCTs and 3 cohort studies. ‡NYHA functional class available in 18 RCTs and
cohort studies.
NYHA  New York Heart Association; RCT  randomized controlled trial.rticles were identified from references in the articles re-
arieved; thus, a total of 96 full-text articles were collected.
owever, 64 of them were excluded for 1 or more of the
ollowing reasons: duplicate publication, review or meta-
nalysis, lack of pertinence, study protocol, insufficient
nformation provided, or lack of a usual care arm (Fig. 1).
hey are listed in the Online Appendix together with the
eason for exclusion. Thus, 20 RCTs (3–22) and 12 cohort
tudies (23–34) were available. Six cohort studies had a
etween-arm and 6 had a within-arm (before-after) design.
tudy population. As shown in Table 2, RCTs were
venly distributed over the 9 years of literature reviewed, and
of them were published in 2008. Results of cohort studies
tarted to be published only in the year 2001. A limited
roportion of studies (45% of RCTs and 17% of cohort
tudies) had been conducted at multiple centers.
A total of 6,258 patients were enrolled in RCTs and
,354 patients in cohort studies. Women were well repre-
ented (36% and 40% of the study population for RCTs and
ohort studies, respectively). The median age over studies
as 70 years in RCTs and 66 years in cohort studies.
edian left ventricular ejection fraction was 35% in RCTs
nd 40% in cohort studies. Fifty-four percent of patients in
CTs were of New York Heart Association functional class
II to IV compared with 83% of patients in cohort studies.
owever, left ventricular ejection fraction and New York
eart Association functional class were only very partially
etrievable and thus are to be interpreted with caution.
Median follow-up duration was 6 months, and approxi-
ately 25% of the follow-up was 3 months or less in RCTs.
n contrast, median follow-up duration was 12 months in
ohort studies; only 1 study had a follow-up of 3 months or
ess. One-half of the RCTs had a high-quality scoring (8)
ompared with only 17% of cohort studies.
PM approach (telephone and technology-assisted
onitoring). Among the RCTs, 2 studies (3,5) compared
strategies (usual care, telephone monitoring, and
echnology-assisted monitoring), whereas the remaining 18
attern of Follow-Up and Monitoringpproach in the 32 Stu ies I cludedTable 3 Pattern of Follow-Up and MonitoringApproach in the 32 Studies Included
Pattern of Follow-Up RCT* Cohort Study
Usual care† 20 12
Family physician 10 2
Home care service 2 1
Cardiologist 4 0
Not specified 9 9
Telephone-monitoring approach 13 0
Phone call 12 —
Phone call  home visit 1 —
Technology-assisted approach 9 12
Home-monitoring equipment 6 11
Implantable device 1 1
Phone call with decision support system 2 0
The total number of RCTs is 20, with a total number of RPM arms of 22 (2 studies with 2 RPM
rms each). †Multiple choices allowed.
RCT  randomized controlled trial.
S*
m
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Figure 2 Parameters Monitored in RCTs and Cohort Studies
ECG  electrocardiogram; RCT  randomized controlled trial; RV  right ventricular.tudy Outcome Summary: Event Incidence (Incidence Rate) and 95% Confidence IntervalTable 4 Study Outcome Summary: Event Incidence (Incidence Rate) and 95% Confidence Interval
Study Outcome RPM Ntot Nev PY
Cumulative Incidence, %
(95% CI)
Incidence Rate per 100 PY
(95% CI)
RCT
Death No 2,813 397 2,675.2 14.1 (12.8–15.4) 14.8 (13.5–16.4)
Yes 3,320 390 3,321.9 11.7 (10.7–12.9) 11.7 (10.7–13.0)
Telephone monitoring 2,598 312 2,934.5 12.0 (10.8–13.3) 10.6 (9.5–11.9)
Technology assisted 722 78 387.4 10.8 (8.6–13.3) 20.1 (15.9–2.1)
Patients hospitalized No 1,985 901 1,915.1 45.4 (43.2–47.6) 47.0 (44.0–50.2)
Yes 2,137 918 2,035.8 43.0 (40.8–45.1) 45.1 (42.2–48.1)
Telephone monitoring 1,662 670 1,752.9 40.3 (37.9–42.7) 38.2 (37.9–42.7)
Technology assisted 475 248 282.9 52.2 (47.6–56.8) 87.6 (0.77–0.99)
Patients hospitalized for HF No 2,079 546 1,986.4 26.3 (24.4–28.2) 27.4 (25.2–29.9)
Yes 2,231 424 2,103.4 19.0 (17.4–20.7) 20.2 (18.3–22.2)
Telephone monitoring 1,735 302 1,828.2 17.4 (15.6–19.3) 16.5 (14.7–18.5)
Technology assisted 496 122 275.2 24.6 (20.9–28.6) 45.4 (43.2–47.6)
Combined end point No 1,090 553 1,279.1 50.7 (47.7–53.7) 43.2 (39.7–47.0)
Yes 1,348 608 1,452.1 38.9 (30.7–35.1) 41.9 (38.6–45.3)
Telephone monitoring 1,185 525 1,343.4 44.3 (41.4–47.1) 39.1 (35.8–42.6)
Technology assisted 163 83 108.7 50.9 (43.0–58.8) 76.4 (60.8–94.7)
Cohort (between)
Death No 945 123 808.2 13.0 (10.9–15.3) 15.2 (12.6–18.1)
Yes 980 67 839.7 6.8 (5.3–8.6) 8.0 (6.2–10.1)
Patients hospitalized No 399 153 331.3 38.3 (33.5–43.3) 46.2 (39.1–54.1)
Yes 420 84 348.8 20.0 (16.3–24.1) 24.1 (19.2–29.8)
Patients hospitalized for HF No 124* 48 72.3 38.7 (30.1–47.9) 66.4 (49.0–88.0)
Yes 158* 19 92.2 12.0 (7.4–18.1) 20.6 (12.4–32.2)
Combined end point No 96* 15 80.0 15.6 (9.0–24.4) 18.7 (10.5–30.1)
Yes 32* 3 26.7 9.4 (2.0–25.0) 11.2 (2.3–32.8)
Single study; in cohort study, RPM is always technology assisted.
CI  confidence interval; HF  heart failure; Nev  number of patients with event/number of events; Ntot  total number of patients; Pts  patients; PY  person-years ( mean follow-up per arm in
onths  number of patients per arm/12); RPM  remote patient monitoring.
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Remote Patient Monitoring in Heart Failure October 27, 2009:1683–94tudies (4,6–22) compared the usual care approach with the
elephone-monitoring approach (11 studies) or technology-
ssisted monitoring approach (7 studies). In contrast, in all
ohort studies, the usual care approach was always compared
ith the technology-assisted monitoring approach. Detailed
M-H Overall  (I-squared = 0.0%, p = 0.825)
study
GESICA Investigators et al, 2005
Barrth et al, 2001
Galbreath et al, 2004
Sisk et al, 2006
Bourge et al, 2008
Jerant et al, 2001
Krumholz et al, 2002
Schwarz et al, 2008
D+L Overall
DeBusk et al, 2004
Riegel et al, 2006
Cleland et al, 2005
Kashem et al, 2008
Blue et al, 2001
Dunagan et al, 2005
McDonald et al, 2002
Riegel et al, 2002
Goldberg et al, 2003
Kasper et al, 2002
Laramee et al, 2003
RPM reduces risk  
1.1 .5 1
RPM & death
A
M-H Overall  (I-squared = 18.4%, p = 0.268)
Laramee et al, 2003
Riegel et al, 2002
Dunagan et al, 2005
Schwarz et al, 2008
Blue et al, 2001
Riegel et al, 2006
Woodend et al, 2008
study
GESICA Investigators et al, 2005
DeBusk et al, 2004
Sisk et al, 2006
D+L Overall
Cleland et al, 2005
RPM reduces risk  RPM in
1.5
RPM & Hosp
B
Figure 3 Forrest Plots for the Analysis of the Primary End Poin
(A) Association of remote patient monitoring (RPM) and death. (B) Association ofethodology of care in the analyzed studies is given in wable 3. Of note, in 9 of 20 RCTs and in 9 of 12 cohort
tudies, the modality for performing usual care was not
rovided.
In RCTs, symptoms and body weight were always re-
orded. In a similar manner, symptoms and body weight
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hysical activity, and heart rate were monitored in a limited
umber of RCTs (5 of 20 studies); in contrast, blood
ressure and heart rate were monitored twice as frequently
n cohort studies than in RCTs (7 of 12 studies and 8 of 12
D
M-H Overall  (I-squared = 58.9%, p = 0.045)
study
Myers S et al, 2006
D+L Overall
Gambetta et al, 2007
Morguet et al, 2008
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he total number of patients, the total number of patients
ith events, and the person-years of observation.
In the cohort studies with a before-after design, the
ncidence rate of hospitalization was calculated over 4
tudies and equaled 86.4 (95% CI: 75.7 to 98.3) in the study
eriod with the usual care approach and 21.1 per 100
erson-years (95% CI: 16.0 to 27.4) in the study period with
he RPM approach. The incidence rate of hospitalization
or HF was calculated over 2 studies and equaled 100%
95% CI: 98% to 100%) in the study period with the usual
are approach and 28.4 per 100 person-years (95% CI: 21.1
o 37.3) in the study period with the RPM approach.
verall, the incidence of death, hospitalization for all
auses, hospitalization for HF, or combined death and
ospitalization was lower with the RPM compared with the
sual care approach.
utcomes in RCTs. The association of the RPM ap-
roach with death, hospitalization, hospitalization for HF,
nd the combined outcome of death and hospitalization is
hown in Figure 3 and summarized in Table 5.
RPM was associated with a significantly lower number of
eaths (RR: 0.83, 95% CI: 0.73 to 0.95, p  0.006)
ompared with usual care (Fig. 3A). No heterogeneity
etween studies was shown (p  0.82). A similar, yet less
mportant, protective effect was found comparing RPM
ith usual care when hospitalization was considered (RR:
.93, 95% CI: 0.87 to 0.99, p  0.030); the higher
eterogeneity (18.4%, p  0.27) resulted in a loss of
tatistical significance when considering the random-effects
R (Fig. 3B). The strongest protective effect of RPM
ompared with usual care was found when hospitalization
or HF was analyzed (RR: 0.71, 95% CI: 0.64 to 0.80, p 
.001) with little heterogeneity between studies (Fig. 3C).
he combined end point of death and first hospitalization
available in a few studies) gave comparable results (RR:
.86, 95% CI: 0.79 to 0.94, p 0.001). Some heterogeneity
as present (28%, p  0.22), although without loss of
ignificance in the random-effects model (Fig. 3D).
In a sensitivity analysis, the telephone or technology-
ssisted monitoring approach provided an equally large
enefit compared with usual care for almost every outcome.
f note, the protective effect on death of the technology-
ssisted approach was slightly greater than that provided by
he structured telephone approach (Table 5). Moreover,
hen RRs were computed separately according to duration
f follow-up (short/long) and to quality of study (low/high),
he association between RPM and death or RPM and
ospitalization for HF was maintained (Table 5).
utcomes in cohort studies. Figure 4 shows the effect of
PM on death and hospitalization. RPM was associated
ith a significantly lower number of deaths (random-effects
R: 0.53, 95% CI: 0.29 to 0.96, p  0.001) and hospital-
zations (random-effects RR: 0.52, 95% CI: 0.28 to 0.96, p 
.001) compared with usual care. High heterogeneity between wtudies was shown (I2  59% for death and I2  82% for
ospitalization) (Figs. 4A and 4B).
iscussion
his meta-analysis showed that RPM significantly reduced
he risk of death, hospitalization for any cause, and hospi-
alization for HF compared with usual care in RCTs. The
eduction in risk of death and hospitalization was even more
ronounced when meta-analyzing cohort studies.
Our analysis confirms, extends, and updates previous sys-
ematic reviews (35–38). To the best of our knowledge, this
epresents the largest number of meta-analyzed patients. A
reviously published analysis (35) included 14 RCTs (all
ublished before May 2006) and totaled 4,369 patients; in
ontrast, our analysis included 20 RCTs (all published before
ctober 2008) and reported on 6,133 patients, which repre-
ents 1,764 patients or 40.3% more patients than the most
ecent meta-analysis of RCTs by Clark et al. (35). Since the
ublication of that meta-analysis, 5 additional RCTs were
ublished, including 4 in 2008 (6,9,10,21); moreover, nearly all
ohort studies included in our meta-analysis were published in
he past 5 years. That clearly indicates a growing interest in
PM in the cardiology community; a similarly great interest in
elemedicine is also found at the highest European institutional
evel, which recently urged health care systems across Europe
o embrace the technology. There are, however, technological
nd organizational challenges for health care systems that are
xpected to increase in view of the aging population in Western
ountries and the increase in the prevalence of HF in the
eneral population worldwide. Which parameters to monitor,
ow to monitor them most efficiently, and how to organize the
esponse of the health care professionals to data obtained from
onitoring to optimize patient care are all questions that need
o be answered.
In contrast to most previous reviews and meta-analyses,
ur study included both RCTs and cohort studies. RCTs
re very accurate in their design but may not reflect real life
ell enough, which, in contrast, is probably better repre-
ented in cohort studies; conversely, cohort studies often do
ot sufficiently control for confounding factors. The fact
hat the use of RPM in cohort studies led to a reduction of
oth mortality and hospitalization, which was of similar
agnitude or even greater than that observed in RCTs, may
e considered a confirmation of the value of the technology
s such. This observation also emphasizes the importance of
ncluding in meta-analyses both RTCs and cohort studies.
here are additional differences between this meta-analysis
nd most of the previous meta-analyses; indeed, our meta-
nalysis and that of Clark et al. (35) considered only those
tudies in which RPM was compared with usual care. These
riteria are more stringent than those of other meta-analyses
36–38), which included different multidisciplinary ap-
roaches. The beneficial effect of RPM on mortality and
ospitalization observed in our meta-analysis was consistent
ith that reported by Clark et al. (35) (Table 6), who, however,
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omparing the results of our meta-analysis with those of a
revious review of cohort studies by Gonseth et al. (36). They
ncluded cohort studies that were published before 2004 and
ummarized the data of comprehensive disease management
rograms and very little, if any, of technology-assisted RPM.
elemonitoring technology has substantially changed over the
ast years and has moved from structured phone contact to
ore automatic external, wearable, or implantable devices
21,31,39). In addition, modern technology relies more and
ore on central servers, sophisticated algorithms for automatic
eview of transmitted data and alerts, expert systems for direct
nteraction with either the patient or health care provider, and
edicated online health care providers and in-hospital remote
evice and disease management units (39,40).
Although well-designed cohort studies may be as
ccurate as RCTs (41,42), they should be considered with
aution because they often do not sufficiently control for
onfounding factors, thus resulting in high estimates of
isk. As a matter of fact, the estimates of the pooled risk
eta-Analysis of the Selected OutcomesTable 5 Meta-Analysis of the Selected Outcomes
Death Pa
End Point n* RR (95% CI) n*
Primary end point
RPM vs. usual care 18 11
Fixed 0.83 (0.73–0.95)
Random 0.84 (0.73–0.95)
Heterogeneity (I2 and p) 0%
Sensitivity analyses
Telephone monitoring vs. usual care 12 7
Fixed 0.86 (0.74–0.99)
Random 0.86 (0.74–0.99)
Heterogeneity (I2) 0%
Technology-assisted vs. usual care 7 5
Fixed 0.72 (0.55–0.95)
Random 0.73 (0.55–0.96)
Heterogeneity (I2) 0%
RPM vs. usual care if FU 6 months 9 5
Fixed 0.74 (0.56–0.97)
Random 0.74 (0.56–0.98)
Heterogeneity (I2) 0%
RPM vs. usual care if FU 6 months 9 6
Fixed 0.86 (0.74–1.00)
Random 0.86 (0.74–1.00)
Heterogeneity (I2) 0%
RPM vs. usual care if quality 8 8 3
Fixed 0.70 (0.54–0.90)
Random 0.70 (0.54–0.90)
Heterogeneity (I2) 0%
RPM vs. usual care if quality 8 10 8
Fixed 0.89 (0.76–1.04)
Random 0.89 (0.76–1.03)
Heterogeneity (I2) 0%
n  number of studies.
FU  follow-up; RR  relative risk; other abbreviations as in Table 4.eduction of death and hospitalization in the cohort atudies in our meta-analysis were unadjusted for con-
ounding, which resulted in an almost 50% risk reduction
ompared with at best 20% in the RCTs (Table 6).
oreover, only a few cohort studies satisfied our inclu-
ion criteria, leading to wide CIs for the estimates of RR.
n additional caveat exists regarding the interpretation of
bservational studies included in this meta-analysis be-
ause enrollment in the RPM arm was voluntary; this
ight bias the results toward a high adherence to the
onitoring program given the high level of motivation of
hese patients and resulting in a lower incidence of
vents. Moreover, clinical, social, and/or demographic
actors may be considered additional confounders and
hould be adjusted for in any analysis. All these reasons
mphasize the difficulty in stating a difference in effect
ize between RCTs and cohort studies. It is important to
ote that same drawbacks apply to a previous meta-
nalysis and explain the similar large differences observed
etween estimates of risk reduction in RCTs and cohort
tudies (36). Future cohort studies should be designed to
Hospitalized Patients Hospitalized HF Combined
RR (95% CI) n* RR (95% CI) n* RR (95% CI)
12 6
.93 (0.87–0.99) 0.71 (0.63–0.80) 0.86 (0.79–0.94)
.96 (0.90–1.03) 0.72 (0.64–0.81) 0.85 (0.77–0.95)
18% 2% 28%
9 6
.92 (0.85–0.99) 0.70 (0.62–0.80) 0.86 (0.79–0.94)
.92 (0.85–0.99) 0.70 (0.60–0.82) 0.86 (0.77–0.95)
0% 14% 31%
4 1
.94 (0.84–1.06) 0.74 (0.61–0.91)
.97 (0.85–1.12) 0.75 (0.61–0.92)
44% 0%
5 1
.98 (0.87–1.11) 0.68 (0.55–0.83)
.02 (0.94–1.12) 0.70 (0.54–0.92)
6% 35%
7 5
.91 (0.84–0.98) 0.73 (0.64–0.83) 0.87 (0.80–0.95)
.91 (0.84–0.99) 0.72 (0.63–0.83) 0.87 (0.80–0.94)
0% 0% 0%
3 1
.06 (0.91–1.24) 0.63 (0.49–0.82)
.06 (0.97–1.15) 0.63 (0.39–1.03)
0% 56%
9 5
.91 (0.84–0.98) 0.73 (0.64–0.83) 0.87 (0.80–0.95)
.91 (0.85–0.98) 0.73 (0.64–0.82) 0.87 (0.80–0.94)
0% 0% 0%tients
0
0
0
0
0
0
0
1
0
0
1
1
0
0ssess the role of RPM in large populations having as end
p
a
i
i
a
t
g
h
C
s
U
a
i
i
u
t
T
i
r
1692 Klersy et al. JACC Vol. 54, No. 18, 2009
Remote Patient Monitoring in Heart Failure October 27, 2009:1683–94oints death and hospitalization (any cause and HF) while
ccounting for the underlying patients’ characteristics.
Because RPM exclusively collects symptom and physiolog-
cal data related to HF, a greater effect on death or hospital-
zation from HF rather than on death or hospitalization from
ny cause was expected. In keeping with the stated hypothesis,
he protective effect of RPM on hospitalization for HF was
reater than on hospitalizations for any cause. The reduction in
ospitalization for HF (7%) was similar to that found in the
lark et al. (35) meta-analysis (5%) and was statistically
M-H Overall  (I-squared = 58.9%, p = 0.045)
study
Myers S et al, 2006
D+L Overall
Gambetta et al, 2007
Morguet et al, 2008
Scalvini et al, 2006
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Kielblock et al, 2007
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1.1 .5 2
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Figure 4 Forrest Plots for the Analysis of the Primary End Poin
(A) Association of RPM and death. (B) Association of RPM and hospitalization. Seignificant in our meta-analysis due to the larger sample size. mnfortunately, only hospitalizations for HF could be meta-
nalyzed here, given the scarce information on cause of death
n the selected articles. However, RPM also showed a signif-
cant protective effect on death from any cause in our review;
sually elderly patients would have comorbidities, and some of
hese may have been exacerbated by their cardiac condition.
hus, better follow-up and care for the latter might have also
ncreased their overall well-being and survival.
Particular care was taken to evaluate the robustness of our
esults in a series of sensitivity analyses. We did not observe
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ow-quality of the study. Similarly, risk reduction was
onsistent for all outcomes when evaluating separately the
elephone and technology-assisted approach, despite these 2
pproaches being inherently different. This is in line with
he results of the only 2 available articles that directly
ompared these 2 modalities (3,5). Similar results were
eported by Gonseth et al. (36) and Roccaforte et al. (38),
hereas others have reported that regularly scheduled struc-
ured telephone contact, referral to a family physician
36–38), and monitoring of symptoms alone (35) were less
ffective in reducing risk than more comprehensive moni-
oring approaches (Table 6).
The heterogeneity of RCTs was small in this review and
ower than that reported by Roccaforte et al. (38) (40% to
0%), but comparable to that reported by Clark et al. (35).
ne possible explanation for this discrepancy may reside in
he fact that Clark et al. (35) considered older studies, a
ore general intervention pattern, and possibly the fact that
he usual care arm included a large variety of situations.
uch greater heterogeneity was observed for cohort studies
50%), although this was less than the heterogeneity re-
orted by Gonseth et al. (36) (60% to 85%); this might be
ue to both the lack of control of confounders and the
election bias in the enrollment process of either arms.
onclusions
he results of this meta-analysis support the benefit of
PM on mortality and hospitalization rates. This benefit
as present in both RCTs and cohort studies. This analysis
rovides further support for the recent recommendation by
uropean and American scientific societies. Mid- and
ong-term cost-effectiveness of remote patient monitoring,
owever, remains to be evaluated.
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APPENDIX
or a table showing the study excluded and reason for exclusion as well as
unnel plots on cohort and RCT studies, please see the online version of
his article.
